{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:17:09Z","timestamp":1787901429641,"version":"build-2784847793"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"DOI":"10.1007\/s11154-026-10079-w","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:26:23Z","timestamp":1787898383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FGF23\u3000\u2013 A hormone produced by bone and has many faces \u2013"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-3469","authenticated-orcid":false,"given":"Seiji","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"3","key":"10079_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/81664","volume":"26","author":"ADHR Consortium","year":"2000","unstructured":"ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26(3):345\u20138. https:\/\/doi.org\/10.1038\/81664.","journal-title":"Nat Genet"},{"issue":"2","key":"10079_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1006\/bbrc.2000.3696","volume":"277","author":"T Yamashita","year":"2000","unstructured":"Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277(2):494\u20138. https:\/\/doi.org\/10.1006\/bbrc.2000.3696.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"10079_CR3","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98(11):6500\u20135. https:\/\/doi.org\/10.1073\/pnas.101545198.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"39","key":"10079_CR4","doi-asserted-by":"publisher","first-page":"37419","DOI":"10.1074\/jbc.M304544200","volume":"278","author":"S Liu","year":"2003","unstructured":"Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003;278(39):37419\u201326. https:\/\/doi.org\/10.1074\/jbc.M304544200.","journal-title":"J Biol Chem"},{"issue":"3","key":"10079_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/jbmr.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429\u201335. https:\/\/doi.org\/10.1359\/jbmr.0301264.","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10079_CR6","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1210\/jc.2002-021105","volume":"87","author":"Y Yamazaki","year":"2002","unstructured":"Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia. J Clin Endocrinol Metab. 2002;87(11):4957\u201360. https:\/\/doi.org\/10.1210\/jc.2002-021105.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10079_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00441-010-1024-2","volume":"342","author":"N Itoh","year":"2010","unstructured":"Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res. 2010;342(1):1\u201311. https:\/\/doi.org\/10.1007\/s00441-010-1024-2.","journal-title":"Cell Tissue Res"},{"issue":"9","key":"10079_CR8","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1128\/mcb.02249-06","volume":"27","author":"R Goetz","year":"2007","unstructured":"Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol. 2007;27(9):3417\u201328. https:\/\/doi.org\/10.1128\/mcb.02249-06.","journal-title":"Mol Cell Biol"},{"issue":"5013","key":"10079_CR9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1126\/science.1646484","volume":"252","author":"AC Rapraeger","year":"1991","unstructured":"Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science. 1991;252(5013):1705\u20138. https:\/\/doi.org\/10.1126\/science.1646484.","journal-title":"Science."},{"issue":"4","key":"10079_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/0092-8674(91)90512-w","volume":"64","author":"A Yayon","year":"1991","unstructured":"Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 1991;64(4):841\u20138. https:\/\/doi.org\/10.1016\/0092-8674(91)90512-w.","journal-title":"Cell"},{"issue":"10","key":"10079_CR11","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1074\/jbc.C500457200","volume":"281","author":"H Kurosu","year":"2006","unstructured":"Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281(10):6120\u20133. https:\/\/doi.org\/10.1074\/jbc.C500457200.","journal-title":"J Biol Chem."},{"issue":"7120","key":"10079_CR12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770\u20134. https:\/\/doi.org\/10.1038\/nature05315.","journal-title":"Nature."},{"issue":"8","key":"10079_CR13","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1359\/jbmr.060507","volume":"21","author":"SM Burnett","year":"2006","unstructured":"Burnett SM, Gunawardene SC, Bringhurst FR, J\u00fcppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006;21(8):1187\u201396. https:\/\/doi.org\/10.1359\/jbmr.060507.","journal-title":"J Bone Miner Res."},{"issue":"3","key":"10079_CR14","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1210\/jc.2004-1039","volume":"90","author":"SL Ferrari","year":"2005","unstructured":"Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005;90(3):1519\u201324. https:\/\/doi.org\/10.1210\/jc.2004-1039.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10079_CR15","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1074\/jbc.M408903200","volume":"280","author":"H Saito","year":"2005","unstructured":"Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005;280(4):2543\u20139. https:\/\/doi.org\/10.1074\/jbc.M408903200.","journal-title":"J Biol Chem."},{"issue":"23","key":"10079_CR16","doi-asserted-by":"publisher","first-page":"11418","DOI":"10.1073\/pnas.1815166116","volume":"116","author":"Y Takashi","year":"2019","unstructured":"Takashi Y, Kosako H, Sawatsubashi S, Kinoshita Y, Ito N, Tsoumpra MK, et al. Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation. Proc Natl Acad Sci U S A. 2019;116(23):11418\u201327. https:\/\/doi.org\/10.1073\/pnas.1815166116.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10079_CR17","doi-asserted-by":"crossref","unstructured":"Brown WW, Juppner H, Langman CB, Price H, Farrow EG, White KE, et al. Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen\u2019s metaphyseal chondrodysplasia. J Clin Endocrinol Metab. 2009;94(1):17\u201320. http:\/\/doi.org\/10.1210\/jc.2008-022010.1210\/jcem.94.2.9988.","DOI":"10.1210\/jc.2008-0220"},{"issue":"11","key":"10079_CR18","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ng1905","volume":"38","author":"JQ Feng","year":"2006","unstructured":"Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38(11):1310\u20135. https:\/\/doi.org\/10.1038\/ng1905.","journal-title":"Nat Genet."},{"issue":"11","key":"10079_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae307","volume":"17","author":"A Hamroun","year":"2024","unstructured":"Hamroun A, Boukrout N, Cauffiez C, Fellah S, Van der Hauwaert C, Pottier N, et al. Severe hypophosphatemia induced by excessive production of FGF23 in acute hepatitis: from bedside to bench. Clin Kidney J. 2024;17(11):sfae307. https:\/\/doi.org\/10.1093\/ckj\/sfae307.","journal-title":"Clin Kidney J"},{"key":"10079_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101144","volume":"15","author":"N Hidaka","year":"2021","unstructured":"Hidaka N, Kato H, Koga M, Katsura M, Oyama Y, Kinoshita Y, et al. Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption. Bone Rep. 2021;15: 101144. https:\/\/doi.org\/10.1016\/j.bonr.2021.101144.","journal-title":"Bone Rep."},{"issue":"5","key":"10079_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMc2405746","volume":"392","author":"Y Hoshino","year":"2025","unstructured":"Hoshino Y, Okamoto K, Ogawa T, Kato H, Irie K, Watanabe S, et al. Acquired Osteomalacia Associated with Autoantibodies against PHEX. N Engl J Med. 2025;392(5):513\u20135. https:\/\/doi.org\/10.1056\/NEJMc2405746.","journal-title":"N Engl J Med."},{"issue":"4","key":"10079_CR22","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1359\/jbmr.070107","volume":"22","author":"EA Imel","year":"2007","unstructured":"Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007;22(4):520\u20136. https:\/\/doi.org\/10.1359\/jbmr.070107.","journal-title":"J Bone Miner Res."},{"issue":"17","key":"10079_CR23","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa020881","volume":"348","author":"KB Jonsson","year":"2003","unstructured":"Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348(17):1656\u201363. https:\/\/doi.org\/10.1056\/NEJMoa020881.","journal-title":"N Engl J Med."},{"issue":"8","key":"10079_CR24","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/jbmr.3155","volume":"32","author":"N Kamiya","year":"2017","unstructured":"Kamiya N, Yamaguchi R, Aruwajoye O, Kim AJ, Kuroyanagi G, Phipps M, et al. Targeted Disruption of NF1 in Osteocytes Increases FGF23 and Osteoid With Osteomalacia-like Bone Phenotype. J Bone Miner Res. 2017;32(8):1716\u201326. https:\/\/doi.org\/10.1002\/jbmr.3155.","journal-title":"J Bone Miner Res."},{"issue":"2","key":"10079_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ajhg.2010.01.010","volume":"86","author":"V Levy-Litan","year":"2010","unstructured":"Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet. 2010;86(2):273\u20138. https:\/\/doi.org\/10.1016\/j.ajhg.2010.01.010.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10079_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jaad.2015.11.012","volume":"75","author":"YH Lim","year":"2016","unstructured":"Lim YH, Ovejero D, Derrick KM, Collins MT, Choate KA. Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy. J Am Acad Dermatol. 2016;75(2):420\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2015.11.012.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10079_CR27","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/ng1868","volume":"38","author":"B Lorenz-Depiereux","year":"2006","unstructured":"Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38(11):1248\u201350. https:\/\/doi.org\/10.1038\/ng1868.","journal-title":"Nat Genet."},{"issue":"2","key":"10079_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajhg.2010.01.006","volume":"86","author":"B Lorenz-Depiereux","year":"2010","unstructured":"Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet. 2010;86(2):267\u201372. https:\/\/doi.org\/10.1016\/j.ajhg.2010.01.006.","journal-title":"Am J Hum Genet."},{"issue":"6","key":"10079_CR29","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/jbmr.1850","volume":"28","author":"SH Rafaelsen","year":"2013","unstructured":"Rafaelsen SH, Raeder H, Fagerheim AK, Knappskog P, Carpenter TO, Johansson S, et al. Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification. J Bone Miner Res. 2013;28(6):1378\u201385. https:\/\/doi.org\/10.1002\/jbmr.1850.","journal-title":"J Bone Miner Res."},{"issue":"5","key":"10079_CR30","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1172\/jci18399","volume":"112","author":"M Riminucci","year":"2003","unstructured":"Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112(5):683\u201392. https:\/\/doi.org\/10.1172\/jci18399.","journal-title":"J Clin Invest."},{"key":"10079_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115055","volume":"129","author":"SK Sahoo","year":"2019","unstructured":"Sahoo SK, Kushwaha P, Bharti N, Khedgikar V, Trivedi R, Agrawal V, et al. Elevated FGF23 in a patient with hypophosphatemic osteomalacia associated with neurofibromatosis type 1. Bone. 2019;129: 115055. https:\/\/doi.org\/10.1016\/j.bone.2019.115055.","journal-title":"Bone."},{"issue":"Pt 2","key":"10079_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1258\/acb.2008.008151","volume":"46","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009;46(Pt 2):167\u20139. https:\/\/doi.org\/10.1258\/acb.2008.008151.","journal-title":"Ann Clin Biochem."},{"issue":"4","key":"10079_CR33","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","volume":"45","author":"Y Shimizu","year":"2009","unstructured":"Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009;45(4):814\u20136. https:\/\/doi.org\/10.1016\/j.bone.2009.06.017.","journal-title":"Bone."},{"issue":"2","key":"10079_CR34","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-4453","volume":"138","author":"H Wasserman","year":"2016","unstructured":"Wasserman H, Ikomi C, Hafberg ET, Miethke AG, Bove KE, Backeljauw PF. Two Case Reports of FGF23-Induced Hypophosphatemia in Childhood Biliary Atresia. Pediatrics. 2016;138(2): e20154453. https:\/\/doi.org\/10.1542\/peds.2015-4453.","journal-title":"Pediatrics."},{"issue":"2","key":"10079_CR35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1086\/427956","volume":"76","author":"KE White","year":"2005","unstructured":"White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet. 2005;76(2):361\u20137. https:\/\/doi.org\/10.1086\/427956.","journal-title":"Am J Hum Genet."},{"issue":"10","key":"10079_CR36","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.1210\/jc.2005-0301","volume":"90","author":"K Araya","year":"2005","unstructured":"Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab. 2005;90(10):5523\u20137. https:\/\/doi.org\/10.1210\/jc.2005-0301.","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"10079_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/hmg\/ddi034","volume":"14","author":"A Benet-Pages","year":"2005","unstructured":"Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2005;14(3):385\u201390. https:\/\/doi.org\/10.1093\/hmg\/ddi034.","journal-title":"Hum Mol Genet."},{"issue":"2","key":"10079_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00439-005-0026-8","volume":"118","author":"I Chefetz","year":"2005","unstructured":"Chefetz I, Heller R, Galli-Tsinopoulou A, Richard G, Wollnik B, Indelman M, et al. A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification. Hum Genet. 2005;118(2):261\u20136. https:\/\/doi.org\/10.1007\/s00439-005-0026-8.","journal-title":"Hum Genet."},{"issue":"9","key":"10079_CR39","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1172\/jci31330","volume":"117","author":"S Ichikawa","year":"2007","unstructured":"Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest. 2007;117(9):2684\u201391. https:\/\/doi.org\/10.1172\/jci31330.","journal-title":"J Clin Invest."},{"issue":"12","key":"10079_CR40","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1172\/jci122004","volume":"128","author":"MS Roberts","year":"2018","unstructured":"Roberts MS, Burbelo PD, Egli-Spichtig D, Perwad F, Romero CJ, Ichikawa S, et al. Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies. J Clin Invest. 2018;128(12):5368\u201373. https:\/\/doi.org\/10.1172\/jci122004.","journal-title":"J Clin Invest."},{"issue":"6","key":"10079_CR41","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ng1358","volume":"36","author":"O Topaz","year":"2004","unstructured":"Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004;36(6):579\u201381. https:\/\/doi.org\/10.1038\/ng1358.","journal-title":"Nat Genet."},{"issue":"6655","key":"10079_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/36285","volume":"390","author":"M Kuro-o","year":"1997","unstructured":"Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45\u201351. https:\/\/doi.org\/10.1038\/36285.","journal-title":"Nature."},{"issue":"2","key":"10079_CR43","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1210\/endo.143.2.8657","volume":"143","author":"T Yoshida","year":"2002","unstructured":"Yoshida T, Fujimori T, Nabeshima Y. Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology. 2002;143(2):683\u20139. https:\/\/doi.org\/10.1210\/endo.143.2.8657.","journal-title":"Endocrinology."},{"issue":"4","key":"10079_CR44","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1172\/jci19081","volume":"113","author":"T Shimada","year":"2004","unstructured":"Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561\u20138. https:\/\/doi.org\/10.1172\/jci19081.","journal-title":"J Clin Invest."},{"issue":"7","key":"10079_CR45","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.matbio.2004.09.007","volume":"23","author":"D Sitara","year":"2004","unstructured":"Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004;23(7):421\u201332. https:\/\/doi.org\/10.1016\/j.matbio.2004.09.007.","journal-title":"Matrix Biol."},{"issue":"9","key":"10079_CR46","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1359\/jbmr.080417","volume":"23","author":"Y Yamazaki","year":"2008","unstructured":"Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008;23(9):1509\u201318. https:\/\/doi.org\/10.1359\/jbmr.080417.","journal-title":"J Bone Miner Res."},{"issue":"7689","key":"10079_CR47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature25451","volume":"553","author":"G Chen","year":"2018","unstructured":"Chen G, Liu Y, Goetz R, Fu L, Jayaraman S, Hu MC, et al. alpha-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature. 2018;553(7689):461\u20136. https:\/\/doi.org\/10.1038\/nature25451.","journal-title":"Nature."},{"issue":"11","key":"10079_CR48","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.tig.2004.08.007","volume":"20","author":"N Itoh","year":"2004","unstructured":"Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004;20(11):563\u20139. https:\/\/doi.org\/10.1016\/j.tig.2004.08.007.","journal-title":"Trends Genet."},{"issue":"6807","key":"10079_CR49","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/35039551","volume":"407","author":"L Pellegrini","year":"2000","unstructured":"Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature. 2000;407(6807):1029\u201334. https:\/\/doi.org\/10.1038\/35039551.","journal-title":"Nature."},{"issue":"3","key":"10079_CR50","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/s1097-2765(00)00073-3","volume":"6","author":"J Schlessinger","year":"2000","unstructured":"Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell. 2000;6(3):743\u201350. https:\/\/doi.org\/10.1016\/s1097-2765(00)00073-3.","journal-title":"Mol Cell."},{"issue":"7966","key":"10079_CR51","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41586-023-06155-9","volume":"618","author":"L Chen","year":"2023","unstructured":"Chen L, Fu L, Sun J, Huang Z, Fang M, Zinkle A, et al. Structural basis for FGF hormone signalling. Nature. 2023;618(7966):862\u201370. https:\/\/doi.org\/10.1038\/s41586-023-06155-9.","journal-title":"Nature."},{"issue":"2","key":"10079_CR52","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11914-024-00860-8","volume":"22","author":"S Fukumoto","year":"2024","unstructured":"Fukumoto S. Regulation of FGF23 production in osteocytes. Curr Osteoporos Rep. 2024;22(2):273\u20139. https:\/\/doi.org\/10.1007\/s11914-024-00860-8.","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"10079_CR53","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1172\/jci131190","volume":"130","author":"P Simic","year":"2020","unstructured":"Simic P, Kim W, Zhou W, Pierce KA, Chang W, Sykes DB, et al. Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. J Clin Invest. 2020;130(3):1513\u201326. https:\/\/doi.org\/10.1172\/jci131190.","journal-title":"J Clin Invest"},{"issue":"8","key":"10079_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/jci164610","volume":"133","author":"W Zhou","year":"2023","unstructured":"Zhou W, Simic P, Zhou IY, Caravan P, Vela Parada X, Wen D, et al. Kidney glycolysis serves as a mammalian phosphate sensor that maintains phosphate homeostasis. J Clin Invest. 2023;133(8):e164610. https:\/\/doi.org\/10.1172\/jci164610.","journal-title":"J Clin Invest"},{"key":"10079_CR55","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.molmet.2018.02.007","volume":"11","author":"N Bon","year":"2018","unstructured":"Bon N, Frangi G, Sourice S, Guicheux J, Beck-Cormier S, Beck L. Phosphate-dependent FGF23 secretion is modulated by PiT2\/Slc20a2. Mol Metab. 2018;11:197\u2013204. https:\/\/doi.org\/10.1016\/j.molmet.2018.02.007.","journal-title":"Mol Metab."},{"issue":"1","key":"10079_CR56","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1038\/s41467-019-12399-9","volume":"10","author":"PP Centeno","year":"2019","unstructured":"Centeno PP, Herberger A, Mun HC, Tu C, Nemeth EF, Chang W, et al. Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat Commun. 2019;10(1):4693. https:\/\/doi.org\/10.1038\/s41467-019-12399-9.","journal-title":"Nat Commun."},{"issue":"12","key":"10079_CR57","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, Guti\u00e9rrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370\u20138. https:\/\/doi.org\/10.1038\/ki.2011.47.","journal-title":"Kidney Int."},{"issue":"2","key":"10079_CR58","doi-asserted-by":"publisher","first-page":"F165","DOI":"10.1152\/ajprenal.00311.2024","volume":"328","author":"P Simic","year":"2025","unstructured":"Simic P, Xie H, Zhang Q, Zhou W, Cherukuru R, Adams MA, et al. Glycerol-3-phosphate contributes to the increase in FGF23 production in chronic kidney disease. Am J Physiol Renal Physiol. 2025;328(2):F165-f72. https:\/\/doi.org\/10.1152\/ajprenal.00311.2024.","journal-title":"Am J Physiol Renal Physiol."},{"issue":"4","key":"10079_CR59","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.kint.2019.10.019","volume":"97","author":"KI Akiyama","year":"2020","unstructured":"Akiyama KI, Miura Y, Hayashi H, Sakata A, Matsumura Y, Kojima M, et al. Calciprotein particles regulate fibroblast growth factor-23 expression in osteoblasts. Kidney Int. 2020;97(4):702\u201312. https:\/\/doi.org\/10.1016\/j.kint.2019.10.019.","journal-title":"Kidney Int."},{"issue":"8","key":"10079_CR60","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/jbmr.4620","volume":"37","author":"N Hidaka","year":"2022","unstructured":"Hidaka N, Koga M, Kimura S, Hoshino Y, Kato H, Kinoshita Y, et al. Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia: Outcome of a Retrospective Surveillance. J Bone Miner Res. 2022;37(8):1479\u201388. https:\/\/doi.org\/10.1002\/jbmr.4620.","journal-title":"J Bone Miner Res."},{"issue":"10","key":"10079_CR61","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1210\/jcem.83.10.5167","volume":"83","author":"MJ Econs","year":"1998","unstructured":"Econs MJ, Friedman NE, Rowe PS, Speer MC, Francis F, Strom TM, et al. A PHEX gene mutation is responsible for adult-onset vitamin D-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 1998;83(10):3459\u201362. https:\/\/doi.org\/10.1210\/jcem.83.10.5167.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"10079_CR62","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1210\/jcem.82.2.3765","volume":"82","author":"MJ Econs","year":"1997","unstructured":"Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets\/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab. 1997;82(2):674\u201381. https:\/\/doi.org\/10.1210\/jcem.82.2.3765.","journal-title":"J Clin Endocrinol Metab."},{"key":"10079_CR63","doi-asserted-by":"crossref","unstructured":"Hidaka N, Oyama Y, Koga M, Kondo N, Yasunaga Y, Shimakura T, et al. Excess fibroblast growth factor 23 in alcoholic osteomalacia is derived from the bone. JBMR Plus. 2025;9(3):ziaf010. http:\/\/doi.org\/10.1093\/jbmrpl\/ziaf010","DOI":"10.1093\/jbmrpl\/ziaf010"},{"key":"10079_CR64","doi-asserted-by":"crossref","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381-8. http:\/\/doi.org\/10.1002\/jbmr.340.","DOI":"10.1002\/jbmr.340"},{"key":"10079_CR65","doi-asserted-by":"crossref","unstructured":"Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124(4):1587-97. http:\/\/doi.org\/10.1172\/jci72829.","DOI":"10.1172\/JCI72829"},{"issue":"21","key":"10079_CR66","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, Hogler W, Linglart A, et al. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med. 2018;378(21):1987\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1714641.","journal-title":"N Engl J Med."},{"issue":"2","key":"10079_CR67","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jbmr.4184","volume":"36","author":"Y Imanishi","year":"2021","unstructured":"Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, et al. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia. J Bone Miner Res. 2021;36(2):262\u201370. https:\/\/doi.org\/10.1002\/jbmr.4184.","journal-title":"J Bone Miner Res."},{"issue":"10189","key":"10079_CR68","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/s0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019;393(10189):2416\u201327. https:\/\/doi.org\/10.1016\/s0140-6736(19)30654-3.","journal-title":"Lancet."},{"issue":"7","key":"10079_CR69","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"100","author":"EA Imel","year":"2015","unstructured":"Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, et al. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. J Clin Endocrinol Metab. 2015;100(7):2565\u201373. https:\/\/doi.org\/10.1210\/jc.2015-1551.","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"10079_CR70","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenicky P, Ruppe MD, Portale AA, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018;33(8):1383\u201393. https:\/\/doi.org\/10.1002\/jbmr.3475.","journal-title":"J Bone Miner Res."},{"issue":"12","key":"10079_CR71","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna KL, Rauch F, Kamenicky P, Ito N, Kubota T, Nakamura A, et al. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm. International Trial J Bone Miner Res. 2019;34(12):2183\u201391. https:\/\/doi.org\/10.1002\/jbmr.3843.","journal-title":"International Trial. J Bone Miner Res."},{"key":"10079_CR72","doi-asserted-by":"crossref","unstructured":"Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, et al. Burosumab for the Treatment of Tumor-Induced Osteomalacia. J Bone Miner Res. 2021;36(4):627\u2009\u2212\u200935. http:\/\/doi.org\/10.1002\/jbmr.4233","DOI":"10.1002\/jbmr.4233"},{"issue":"3","key":"10079_CR73","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, et al. Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7(3):189\u201399. https:\/\/doi.org\/10.1016\/s2213-8587(18)30338-3.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10079_CR74","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13023-020-01434-4","volume":"15","author":"R Padidela","year":"2020","unstructured":"Padidela R, Nilsson O, Makitie O, Beck-Nielsen S, Ariceta G, Schnabel D, et al. The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study. Orphanet J Rare Dis. 2020;15(1):172. https:\/\/doi.org\/10.1186\/s13023-020-01434-4.","journal-title":"Orphanet J Rare Dis."},{"issue":"6","key":"10079_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036367","volume":"10","author":"T Kubota","year":"2020","unstructured":"Kubota T, Fukumoto S, Cheong HI, Michigami T, Namba N, Ito N, et al. Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study. BMJ Open. 2020;10(6): e036367. https:\/\/doi.org\/10.1136\/bmjopen-2019-036367.","journal-title":"BMJ Open."},{"key":"10079_CR76","doi-asserted-by":"publisher","first-page":"1471127","DOI":"10.3389\/fendo.2025.1471127","volume":"16","author":"ML Brandi","year":"2025","unstructured":"Brandi ML, Carpenter TO, Fukumoto S, Haffner D, Imel EA, Kanematsu M, et al. Advancing patient evidence in XLH (APEX): rationale and design of a real-world XLH global data unification program. Front Endocrinol (Lausanne). 2025;16:1471127. https:\/\/doi.org\/10.3389\/fendo.2025.1471127.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"3","key":"10079_CR77","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001714","volume":"7","author":"K Briot","year":"2021","unstructured":"Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, et al. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open. 2021;7(3): e001714. https:\/\/doi.org\/10.1136\/rmdopen-2021-001714.","journal-title":"RMD Open."},{"issue":"1","key":"10079_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002676","volume":"9","author":"P Kamenicky","year":"2023","unstructured":"Kamenicky P, Briot K, Brandi ML, Cohen-Solal M, Crowley RK, Keen R, et al. Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD Open. 2023;9(1): e002676. https:\/\/doi.org\/10.1136\/rmdopen-2022-002676.","journal-title":"RMD Open."},{"issue":"3","key":"10079_CR79","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","volume":"107","author":"A Linglart","year":"2022","unstructured":"Linglart A, Imel EA, Whyte MP, Portale AA, H\u00f6gler W, Boot AM, et al. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia. J Clin Endocrinol Metab. 2022;107(3):813\u201324. https:\/\/doi.org\/10.1210\/clinem\/dgab729.","journal-title":"J Clin Endocrinol Metab."},{"key":"10079_CR80","doi-asserted-by":"crossref","unstructured":"Ward LM, H\u00f6gler W, Glorieux FH, Portale AA, Whyte MP, Munns CF, et al. Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period. JBMR Plus. 2024;8(1):ziad001. http:\/\/doi.org\/10.1093\/jbmrpl\/ziad001.","DOI":"10.1093\/jbmrpl\/ziad001"},{"issue":"1","key":"10079_CR81","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/clinem\/dgac518","volume":"108","author":"TJ Weber","year":"2022","unstructured":"Weber TJ, Imel EA, Carpenter TO, Peacock M, Portale AA, Hetzer J, et al. Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia. J Clin Endocrinol Metab. 2022;108(1):155\u201365. https:\/\/doi.org\/10.1210\/clinem\/dgac518.","journal-title":"J Clin Endocrinol Metab."},{"key":"10079_CR82","doi-asserted-by":"publisher","first-page":"204062232412476","DOI":"10.1177\/20406223241247643","volume":"15","author":"AM Boot","year":"2024","unstructured":"Boot AM, Ariceta G, Beck-Nielsen SS, Brandi ML, Briot K, Collantes CL, et al. Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis. Ther Adv Chronic Dis. 2024;15:20406223241247644. https:\/\/doi.org\/10.1177\/20406223241247643.","journal-title":"Ther Adv Chronic Dis."},{"issue":"8","key":"10079_CR83","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/jbmr\/zjaf063","volume":"40","author":"P Florenzano","year":"2025","unstructured":"Florenzano P, Imel EA, Khan AA, Li Z, Vincent M, Nomura T, et al. Real-world effectiveness of burosumab vs oral phosphate and active vitamin D in adults with X-linked hypophosphatemia. J Bone Miner Res. 2025;40(8):973\u201386. https:\/\/doi.org\/10.1093\/jbmr\/zjaf063.","journal-title":"J Bone Miner Res."},{"key":"10079_CR84","doi-asserted-by":"crossref","unstructured":"Linglart A, Amouroux C, Gueorguieva I, Harambat J, Salles JP, Ertl DA, et al. Health-related quality of life in French pediatric patients with X-linked hypophosphatemia: real-world data from the International XLH Registry. JBMR Plus. 2025;9(10):ziaf142. http:\/\/doi.org\/10.1093\/jbmrpl\/ziaf142.","DOI":"10.1093\/jbmrpl\/ziaf142"},{"key":"10079_CR85","doi-asserted-by":"crossref","unstructured":"Michigami T, Kang HG, Namba N, Ito N, Kubota T, Shintani A, et al. Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study. JBMR Plus. 2024;8(8):ziae079. http:\/\/doi.org\/10.1093\/jbmrpl\/ziae079.","DOI":"10.1093\/jbmrpl\/ziae079"},{"key":"10079_CR86","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgag140","author":"LM Ward","year":"2026","unstructured":"Ward LM, Carpenter TO, Cassinelli H, Florenzano P, Imel EA, Khan AA, et al. Real-world Effectiveness of Burosumab Across Age Groups: X-linked Hypophosphatemia (XLH) Disease Monitoring Program. J Clin Endocrinol Metab. 2026. https:\/\/doi.org\/10.1210\/clinem\/dgag140.","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"10079_CR87","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1093\/jbmr\/zjaf079","volume":"40","author":"LM Ward","year":"2025","unstructured":"Ward LM, Imel EA, Frumberg D, Dilworth L, Siener C, Chen Z, et al. Switching from active vitamin D and phosphate supplementation to burosumab significantly corrects lower limb malalignment in pediatric X-linked hypophosphatemia. J Bone Miner Res. 2025;40(12):1332\u201342. https:\/\/doi.org\/10.1093\/jbmr\/zjaf079.","journal-title":"J Bone Miner Res."},{"issue":"8","key":"10079_CR88","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/rheumatology\/kez627","volume":"59","author":"R Amarnani","year":"2020","unstructured":"Amarnani R, Travis S, Javaid MK. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia. Rheumatology (Oxford). 2020;59(8):2166\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kez627.","journal-title":"Rheumatology (Oxford)."},{"issue":"10","key":"10079_CR89","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1210\/clinem\/dgac433","volume":"107","author":"X Bai","year":"2022","unstructured":"Bai X, Levental M, Karaplis AC. Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1). J Clin Endocrinol Metab. 2022;107(10):2777\u201383. https:\/\/doi.org\/10.1210\/clinem\/dgac433.","journal-title":"J Clin Endocrinol Metab."},{"key":"10079_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116004","volume":"150","author":"A Gladding","year":"2021","unstructured":"Gladding A, Szymczuk V, Auble BA, Boyce AM. Burosumab treatment for fibrous dysplasia. Bone. 2021;150: 116004. https:\/\/doi.org\/10.1016\/j.bone.2021.116004.","journal-title":"Bone."},{"key":"10079_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101138","volume":"15","author":"M Khadora","year":"2021","unstructured":"Khadora M, Mughal MZ. Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report. Bone Rep. 2021;15: 101138. https:\/\/doi.org\/10.1016\/j.bonr.2021.101138.","journal-title":"Bone Rep."},{"issue":"5","key":"10079_CR92","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40620-023-01884-6","volume":"37","author":"M Parolin","year":"2024","unstructured":"Parolin M, Partigiani NB, Benetti E, Longo G, Vidal E. The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience. J Nephrol. 2024;37(5):1371\u20134. https:\/\/doi.org\/10.1007\/s40620-023-01884-6.","journal-title":"J Nephrol."},{"key":"10079_CR93","doi-asserted-by":"crossref","unstructured":"Stern R, Levi DS, Gales B, Rutsch F, Salusky IB. Correspondence on \u201cProspective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)\u201d by Ferreira et al. Genet Med. 2021;23(10):2006-7. http:\/\/doi.org\/10.1038\/s41436-021-01228-4","DOI":"10.1038\/s41436-021-01228-4"},{"issue":"8","key":"10079_CR94","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/jbmr.4315","volume":"36","author":"Z Cheng","year":"2021","unstructured":"Cheng Z, O\u2019Brien K, Howe J, Sullivan C, Schrier D, Lynch A, et al. INZ-701 Prevents Ectopic Tissue Calcification and Restores Bone Architecture and Growth in ENPP1-Deficient Mice. J Bone Miner Res. 2021;36(8):1594\u2013604. https:\/\/doi.org\/10.1002\/jbmr.4315.","journal-title":"J Bone Miner Res."},{"issue":"15","key":"10079_CR95","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1021\/acs.jcim.2c00633","volume":"62","author":"SH Liu","year":"2022","unstructured":"Liu SH, Xiao Z, Mishra SK, Mitchell JC, Smith JC, Quarles LD, et al. Identification of Small-Molecule Inhibitors of Fibroblast Growth Factor 23 Signaling via In Silico Hot Spot Prediction and Molecular Docking to \u03b1-Klotho. J Chem Inf Model. 2022;62(15):3627\u201337. https:\/\/doi.org\/10.1021\/acs.jcim.2c00633.","journal-title":"J Chem Inf Model."},{"issue":"6","key":"10079_CR96","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1124\/molpharm.121.000471","volume":"101","author":"Z Xiao","year":"2021","unstructured":"Xiao Z, Liu J, Liu SH, Petridis L, Cai C, Cao L, et al. Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in Hyp Mice. Mol Pharmacol. 2021;101(6):408\u201321. https:\/\/doi.org\/10.1124\/molpharm.121.000471.","journal-title":"Mol Pharmacol."},{"key":"10079_CR97","doi-asserted-by":"crossref","unstructured":"Xiao Z, Riccardi D, Velazquez HA, Chin AL, Yates CR, Carrick JD, et al. A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia. Sci Signal. 2016;9(455):ra113. http:\/\/doi.org\/10.1126\/scisignal.aaf5034","DOI":"10.1126\/scisignal.aaf5034"},{"issue":"1","key":"10079_CR98","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s40610-019-0110-9","volume":"5","author":"JA Wheeler","year":"2019","unstructured":"Wheeler JA, Clinkenbeard EL. Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF. Curr Mol Biol Rep. 2019;5(1):8\u201317. https:\/\/doi.org\/10.1007\/s40610-019-0110-9.","journal-title":"Curr Mol Biol Rep."},{"issue":"8","key":"10079_CR99","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28(8):1793\u2013803. https:\/\/doi.org\/10.1002\/jbmr.1923.","journal-title":"J Bone Miner Res."},{"issue":"2","key":"10079_CR100","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/jbmr.3878","volume":"35","author":"EA Imel","year":"2020","unstructured":"Imel EA, Liu Z, Coffman M, Acton D, Mehta R, Econs MJ. Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets. J Bone Miner Res. 2020;35(2):231\u20138. https:\/\/doi.org\/10.1002\/jbmr.3878.","journal-title":"J Bone Miner Res."},{"issue":"1","key":"10079_CR101","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12916-020-01643-5","volume":"18","author":"IE Emrich","year":"2020","unstructured":"Emrich IE, Lizzi F, Siegel JD, Seiler-Mussler S, Ukena C, Kaddu-Mulindwa D, et al. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study. BMC Med. 2020;18(1):178. https:\/\/doi.org\/10.1186\/s12916-020-01643-5.","journal-title":"BMC Med."},{"issue":"11","key":"10079_CR102","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1007\/s12325-023-02591-1","volume":"40","author":"S Fukumoto","year":"2023","unstructured":"Fukumoto S, Murata T, Osuga Y, Pollock RF. Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials. Adv Ther. 2023;40(11):4877\u201388. https:\/\/doi.org\/10.1007\/s12325-023-02591-1.","journal-title":"Adv Ther."},{"issue":"5","key":"10079_CR103","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. Jama. 2020;323(5):432\u201343. https:\/\/doi.org\/10.1001\/jama.2019.22450.","journal-title":"Jama."},{"issue":"4","key":"10079_CR104","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","volume":"72","author":"H Zoller","year":"2023","unstructured":"Zoller H, Wolf M, Blumenstein I, Primas C, Lindgren S, Thomsen LL, et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut. 2023;72(4):644\u201353. https:\/\/doi.org\/10.1136\/gutjnl-2022-327897.","journal-title":"Gut."},{"issue":"11","key":"10079_CR105","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1182\/blood.2020007172","volume":"137","author":"S Ishii","year":"2021","unstructured":"Ishii S, Suzuki T, Wakahashi K, Asada N, Kawano Y, Kawano H, et al. FGF-23 from erythroblasts promotes hematopoietic progenitor mobilization. Blood. 2021;137(11):1457\u201367. https:\/\/doi.org\/10.1182\/blood.2020007172.","journal-title":"Blood."},{"issue":"14","key":"10079_CR106","doi-asserted-by":"publisher","first-page":"9795","DOI":"10.1074\/jbc.M113.527150","volume":"289","author":"LM Coe","year":"2014","unstructured":"Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem. 2014;289(14):9795\u2013810. https:\/\/doi.org\/10.1074\/jbc.M113.527150.","journal-title":"J Biol Chem."},{"key":"10079_CR107","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025030634","author":"G Courbon","year":"2026","unstructured":"Courbon G, Thomas JJ, Duque EJ, Kentrup D, Spindler J, Semancheck W, et al. Erythroid-produced intact FGF23 is a paracrine inhibitor of erythropoiesis. Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2025030634.","journal-title":"Blood."},{"issue":"1","key":"10079_CR108","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1182\/blood.2022018475","volume":"142","author":"G Courbon","year":"2023","unstructured":"Courbon G, Thomas JJ, Martinez-Calle M, Wang X, Spindler J, Von Drasek J, et al. Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation. Blood. 2023;142(1):106\u201318. https:\/\/doi.org\/10.1182\/blood.2022018475.","journal-title":"Blood."},{"issue":"11","key":"10079_CR109","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/jci46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393\u2013408. https:\/\/doi.org\/10.1172\/jci46122.","journal-title":"J Clin Invest."},{"issue":"6","key":"10079_CR110","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","volume":"22","author":"A Grabner","year":"2015","unstructured":"Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015;22(6):1020\u201332. https:\/\/doi.org\/10.1016\/j.cmet.2015.09.002.","journal-title":"Cell Metab."},{"issue":"6","key":"10079_CR111","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584\u201392. https:\/\/doi.org\/10.1056\/NEJMoa0706130.","journal-title":"N Engl J Med."},{"issue":"11","key":"10079_CR112","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.tem.2018.08.006","volume":"29","author":"Y Takashi","year":"2018","unstructured":"Takashi Y, Fukumoto S. FGF23 beyond Phosphotropic Hormone. Trends Endocrinol Metab. 2018;29(11):755\u201367. https:\/\/doi.org\/10.1016\/j.tem.2018.08.006.","journal-title":"Trends Endocrinol Metab."},{"issue":"15","key":"10079_CR113","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.024952","volume":"11","author":"SH Binnenmars","year":"2022","unstructured":"Binnenmars SH, Hoogslag GE, Yeung SMH, Brouwers FP, Bakker SJL, van Gilst WH, et al. Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study. J Am Heart Assoc. 2022;11(15): e024952. https:\/\/doi.org\/10.1161\/jaha.121.024952.","journal-title":"J Am Heart Assoc."},{"issue":"11","key":"10079_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100723","volume":"5","author":"AS Leidner","year":"2023","unstructured":"Leidner AS, Cai X, Zelnick LR, Lee J, Bansal N, Pasch A, et al. Fibroblast Growth Factor 23 and Risk of Heart Failure Subtype: The CRIC (Chronic Renal Insufficiency Cohort) Study. Kidney Med. 2023;5(11): 100723. https:\/\/doi.org\/10.1016\/j.xkme.2023.100723.","journal-title":"Kidney Med."},{"issue":"5","key":"10079_CR115","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59820","volume":"16","author":"KSS Amaravadi","year":"2024","unstructured":"Amaravadi KSS, Nalisetty P, Vadlamani N, Ibrahimli S, Khan FA, Castillo JA, et al. Impact of Elevated Fibroblast Growth Factor 23 (FGF23) on the Cardiovascular System: A Comprehensive Systematic Literature Review. Cureus. 2024;16(5): e59820. https:\/\/doi.org\/10.7759\/cureus.59820.","journal-title":"Cureus."},{"key":"10079_CR116","doi-asserted-by":"crossref","unstructured":"Hao H, Ma S, Zheng C, Wang Q, Lin H, Chen Z, et al. Excessive fibroblast growth factor 23 promotes renal fibrosis in mice with type 2 cardiorenal syndrome. Aging (Albany NY). 2021;13(2):2982\u20133009. http:\/\/doi.org\/10.18632\/aging.202448","DOI":"10.18632\/aging.202448"},{"issue":"4","key":"10079_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231905","volume":"15","author":"K Kuga","year":"2020","unstructured":"Kuga K, Kusakari Y, Uesugi K, Semba K, Urashima T, Akaike T, et al. Fibrosis growth factor 23 is a promoting factor for cardiac fibrosis in the presence of transforming growth factor-\u03b21. PLoS One. 2020;15(4): e0231905. https:\/\/doi.org\/10.1371\/journal.pone.0231905.","journal-title":"PLoS One."},{"issue":"1","key":"10079_CR118","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/ijms23010166","volume":"23","author":"TW Lee","year":"2021","unstructured":"Lee TW, Chung CC, Lee TI, Lin YK, Kao YH, Chen YJ. Fibroblast Growth Factor 23 Stimulates Cardiac Fibroblast Activity through Phospholipase C-Mediated Calcium Signaling. Int J Mol Sci. 2021;23(1):166. https:\/\/doi.org\/10.3390\/ijms23010166.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"10079_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2022.100003","volume":"103","author":"T Saito","year":"2023","unstructured":"Saito T, Mizobuchi M, Kato T, Ogata H, Koiwa F, Honda H. Fibroblast Growth Factor 23 Exacerbates Cardiac Fibrosis in Deoxycorticosterone Acetate-Salt Mice With Hypertension. Lab Invest. 2023;103(1): 100003. https:\/\/doi.org\/10.1016\/j.labinv.2022.100003.","journal-title":"Lab Invest."},{"issue":"7","key":"10079_CR120","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/biology15070539","volume":"15","author":"L Shen","year":"2026","unstructured":"Shen L, Hu M, Xue M, Li S. FGF23 Controls Myocardial Fibrosis Progression via Promoting Cardiac Fibroblast Proliferation and Activation in Mice. Biology (Basel). 2026;15(7):539. https:\/\/doi.org\/10.3390\/biology15070539.","journal-title":"Biology (Basel)."},{"issue":"4","key":"10079_CR121","doi-asserted-by":"publisher","DOI":"10.1530\/ec-25-0756","volume":"15","author":"S Carrara","year":"2026","unstructured":"Carrara S, Baroncelli GI, Arcidiacono GP, Barale M, Brandi ML, Camozzi V, et al. Clinical features of Italian adult individuals with X-linked hypophosphatemia: a multicenter retrospective study. Endocr Connect. 2026;15(4): e250756. https:\/\/doi.org\/10.1530\/ec-25-0756.","journal-title":"Endocr Connect."},{"key":"10079_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.745892","volume":"9","author":"M Leifheit-Nestler","year":"2021","unstructured":"Leifheit-Nestler M, Wagner MA, Richter B, Piepert C, Eitner F, B\u00f6ckmann I, et al. Cardiac Fibroblast Growth Factor 23 Excess Does Not Induce Left Ventricular Hypertrophy in Healthy Mice. Front Cell Dev Biol. 2021;9: 745892. https:\/\/doi.org\/10.3389\/fcell.2021.745892.","journal-title":"Front Cell Dev Biol."},{"issue":"2","key":"10079_CR123","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.atherosclerosis.2009.05.013","volume":"207","author":"MA Mirza","year":"2009","unstructured":"Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009;207(2):546\u201351. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.05.013.","journal-title":"Atherosclerosis."},{"issue":"4","key":"10079_CR124","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"T Inagaki","year":"2005","unstructured":"Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2(4):217\u201325. https:\/\/doi.org\/10.1016\/j.cmet.2005.09.001.","journal-title":"Cell Metab."},{"issue":"1","key":"10079_CR125","doi-asserted-by":"publisher","DOI":"10.1111\/nep.70156","volume":"31","author":"T Koshida","year":"2026","unstructured":"Koshida T, Nittono H, Takei H, Murakoshi M, Yamashiro Y, Suzuki Y, et al. A Comprehensive Analysis of Serum and Urine Bile Acid Profiles in Chronic Kidney Disease: An Exploratory Study of Clinical Associations. Nephrology (Carlton). 2026;31(1): e70156. https:\/\/doi.org\/10.1111\/nep.70156.","journal-title":"Nephrology (Carlton)."},{"issue":"2","key":"10079_CR126","doi-asserted-by":"publisher","first-page":"e488","DOI":"10.1210\/clinem\/dgad608","volume":"109","author":"A Bouzemane","year":"2024","unstructured":"Bouzemane A, Vignot E, Derain Dubourg L, De Mul A, Molin A, Chapurlat R, et al. Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy. J Clin Endocrinol Metab. 2024;109(2):e488\u201394. https:\/\/doi.org\/10.1210\/clinem\/dgad608.","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-026-10079-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-026-10079-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-026-10079-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:26:26Z","timestamp":1787898386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-026-10079-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":126,"alternative-id":["10079"],"URL":"https:\/\/doi.org\/10.1007\/s11154-026-10079-w","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SF received consultant fee from Kyowa Kirin, Co., Ltd.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}